Skip to content
10-Q

Quarterly Report

TRACON Pharmaceuticals, Inc.

0000950170-24-059752

← back to feed
Filed
May 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 30, 2024 2.68M sh
Shares Diluted Q1 2024 · Mar 31, 2024 2.39M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 1.26M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$2.54M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$5M
Short Term Investments Q1 2024 · Mar 31, 2024 $0
Short Term Investments Q1 2024 · Dec 31, 2023 $0
Cash And Equivalents Q1 2024 · Mar 31, 2024 $7.89M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $8.56M
Stockholders Equity Q1 2024 · Mar 31, 2024 −$1.76M
Stockholders Equity Q1 2024 · Dec 31, 2023 −$809K
Stockholders Equity Q1 2024 · Mar 31, 2023 −$11.07M
Stockholders Equity Q1 2024 · Dec 31, 2022 −$7.15M
Current Liabilities Q1 2024 · Mar 31, 2024 $10.45M
Current Liabilities Q1 2024 · Dec 31, 2023 $10.18M
Current Assets Q1 2024 · Mar 31, 2024 $8.4M
Current Assets Q1 2024 · Dec 31, 2023 $9.09M
Total Assets Q1 2024 · Mar 31, 2024 $9.36M
Total Assets Q1 2024 · Dec 31, 2023 $10.11M
Eps Diluted Q1 2024 · Mar 31, 2024 −$1.33
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$6.76
Eps Basic Q1 2024 · Mar 31, 2024 −$1.33
Eps Basic restated Q1 2024 · Mar 31, 2023 −$6.76
Sga Expense Q1 2024 · Mar 31, 2024 $1.43M
Sga Expense Q1 2024 · Mar 31, 2023 $2.34M
Rd Expense Q1 2024 · Mar 31, 2024 $1.88M
Rd Expense Q1 2024 · Mar 31, 2023 $4.97M
Net Income Q1 2024 · Mar 31, 2024 −$3.17M
Net Income Q1 2024 · Mar 31, 2023 −$8.5M
Operating Income Q1 2024 · Mar 31, 2024 −$3.21M
Operating Income Q1 2024 · Mar 31, 2023 −$7.31M
Revenue Q1 2024 · Mar 31, 2024 $100K